|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2007
gptkb:FDA
|
|
gptkbp:brand
|
Tykerb
|
|
gptkbp:can_be_combined_with
|
gptkb:capecitabine
gptkb:letrozole
gptkb:trastuzumab
|
|
gptkbp:casnumber
|
231277-16-0
|
|
gptkbp:chemical_formula
|
C22 H19 Cl F2 N4 O4 S
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:contraindication
|
liver disease
pregnancy
breastfeeding
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:formulation
|
lapatinib ditosylate
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lapatinib
|
|
gptkbp:indication
|
gptkb:HER2-positive_breast_cancer
metastatic breast cancer
advanced breast cancer
|
|
gptkbp:interacts_with
|
antacids
certain antibiotics
antifungal medications
other cancer medications
|
|
gptkbp:lifespan
|
approximately 24 hours
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
tyrosine kinase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
oral bioavailability 25%
inhibits HER2 and EGFR
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
Category D
|
|
gptkbp:side_effect
|
fatigue
nausea
vomiting
diarrhea
rash
heart problems
|
|
gptkbp:targets
|
gptkb:HER2
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:Erb_B_family
gptkb:HER2-positive_breast_cancer
|
|
gptkbp:bfsLayer
|
6
|